Literature DB >> 9613729

The health burdens of Parkinson's disease.

E A Chrischilles1, L M Rubenstein, M D Voelker, R B Wallace, R L Rodnitzky.   

Abstract

Parkinson's disease (PD) is likely to have a substantial impact on an individual's health-related quality of life (HRQL), health-related resource use, and productivity. Data about the health burdens of PD by disease stage are fundamental to understanding the effectiveness of care, both from a clinical and a fiscal point of view. This study's goal was to describe the associations of patient-reported HRQL and economic characteristics with PD stage. We hypothesized that later stages of PD would be associated with poorer HRQL, greater health-related resource use, and lower work productivity than early stages of PD. We used a cross-sectional analysis to study 193 PD patients attending two hospital-based neurology clinics. Self-administered questionnaires and in-person interviews measured clinical features, functional status, general health perceptions, well-being, overall HRQL, work productivity, and health-related resource use. Consistent, strong associations were found between stage and functional status, general health perceptions, well-being, and overall HRQL even after controlling for age, gender, and comorbid conditions. Most resource use and work productivity measures were also associated with disease stage. However, physician services use was not. This study confirms that the burdens of illness are progressively higher for PD patients with early, moderate, and advanced illness. The results suggest that such important facets of the health burden as HRQL and health-related resource use may be seriously misjudged if not carefully measured but inferred from clinical observations alone.

Entities:  

Mesh:

Year:  1998        PMID: 9613729     DOI: 10.1002/mds.870130306

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  25 in total

1.  Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease.

Authors:  C S Palmer; J K Schmier; E Snyder; B Scott
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

2.  Health related quality of life in Parkinson's disease: a prospective longitudinal study.

Authors:  K H Karlsen; E Tandberg; D Arsland; J P Larsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-11       Impact factor: 10.154

Review 3.  Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.

Authors:  R C Dodel; K Berger; W H Oertel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

4.  The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.

Authors:  R C Dodel; M Singer; R Köhne-Volland; T Szucs; B Rathay; E Scholz; W H Oertel
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

5.  The relative health related quality of life of veterans with Parkinson's disease.

Authors:  H Gage; A Hendricks; S Zhang; L Kazis
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

Review 6.  Potential of APDM mobility lab for the monitoring of the progression of Parkinson's disease.

Authors:  Martina Mancini; Fay B Horak
Journal:  Expert Rev Med Devices       Date:  2016-05       Impact factor: 3.166

7.  Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease.

Authors:  V Fraix; J-L Houeto; C Lagrange; C Le Pen; P Krystkowiak; D Guehl; C Ardouin; M-L Welter; F Maurel; L Defebvre; A Rougier; A-L Benabid; V Mesnage; M Ligier; S Blond; P Burbaud; B Bioulac; A Destée; P Cornu; P Pollak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04       Impact factor: 10.154

8.  Cost of illness and its predictors for Parkinson's disease in Germany.

Authors:  Annika E Spottke; Martin Reuter; Olaf Machat; Bernhard Bornschein; Sonja von Campenhausen; Karin Berger; Rudolf Koehne-Volland; Jürgen Rieke; Alexander Simonow; Dirk Brandstaedter; Uwe Siebert; Wolfgang H Oertel; Gudrun Ulm; Richard Dodel
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 9.  The effect of deep brain stimulation on quality of life in movement disorders.

Authors:  A Diamond; J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

10.  Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.

Authors:  Cynthia S Palmer; Mark J C Nuijten; Jordana K Schmier; Prasun Subedi; Edward H Snyder
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.